CISO Tribune

Disclosure · Form 10-K · fiscal 2025

Oncotelic Therapeutics, Inc. 10-K cybersecurity disclosure (Item 1C), fiscal 2025

Filed April 15, 2026· period ended December 31, 2025· OTLC· CIK 908259· Updated · filing on sec.gov ↗

Oncotelic Therapeutics, Inc.'s Form 10-K for fiscal 2025, filed April 15, 2026, places oversight of cybersecurity risk with the full board; a top security role title is not identified.

What Oncotelic Therapeutics' Item 1C says

Oncotelic Therapeutics' Form 10-K for fiscal 2025 places oversight of cybersecurity risk with the full Board of Directors. The filing says the CEO plays a role in informing the Board of Directors on cybersecurity risks.

Board and management oversight

The full Board of Directors is responsible for oversight of cybersecurity risks because the company has no functional Audit Committee at this time. The CEO briefs the Audit Committee on a regular basis, with a minimum frequency of once per year. The Board plans to establish oversight mechanisms for governance in managing risks associated with cybersecurity threats.

How the company manages cyber risk

The company has integrated cybersecurity risk management into its broader risk management framework. The risk management team works to continuously evaluate and address cybersecurity risks in alignment with business objectives and operational needs.

Third parties and incidents

The company plans to engage external experts, including cybersecurity assessors and auditors, in evaluating and testing its risk management systems. Because the company is aware of risks associated with third-party service providers, it plans to implement processes to oversee and manage these risks. The company plans to conduct security assessments of all third-party providers before engagement and to maintain ongoing monitoring for compliance with its cybersecurity standards. The filing states that the monitoring will include periodic assessments by the company's Chief Executive Officer. The company states it has not encountered cybersecurity challenges that have materially impaired its operations or financial standing.

What the section does not state

The section does not name the person who holds the top security role. The section does not name a specific security framework or standard.

Read from the Form 10-K filed April 15, 2026, on . Every sentence rests on a passage of the section reproduced below.

The filing's fields, each with its sentence

Who leads security (the top role, as the filing names it)

not identified

Reports to

not identified

Board oversight

Full board

“In the absence of a functional Audit Committee at this time, the full Board of Directors is responsible to oversight the cybersecurity risks for the Company.”

CISO or other person named

not identified

Frameworks and standards named

not identified

Outside assessors, consultants or testers

not identified

Experience of the security leadership, as stated

not identified

Material incident

The filing states none

“We have no t encountered cybersecurity challenges that have materially impaired our operations or financial standing.”

The section

457 words, Form 10-K filed April 15, 2026 for the period ended December 31, 2025

Read by claude-sonnet-5-5 on November 12, 2026; every quote verified in the stored text by code.

How peers in the same industry describe the seat

The SEC assigns Oncotelic Therapeutics, Inc. standard industrial classification 2834, Pharmaceutical preparations (SEC SIC list). 8 other filers in our library have the same code.

FilerTop security roleReports toBoard oversight
Nanoviricides, Inc.FY 2026, filed September 28, 2026not identifiednot identifiedaudit committee
Phibro Animal Health CorpFY 2026, filed August 26, 2026Chief Technology and Digital Innovation Officernot identifiedfull board
Protagenic Therapeutics, Inc.\newFY 2026, filed August 14, 2026not identifiednot identifiedaudit committee
Earth Science Tech, Inc.FY 2026, filed June 18, 2026not identifiednot identifiednot identified
GeoVax Labs, Inc.FY 2025, filed April 15, 2026Chief Financial Officernot identifiedNominating and Governance Committee
KALA BIO, Inc.FY 2025, filed April 15, 2026Chief Business Officernot identifiedAudit Committee
Sunshine Biopharma Inc.FY 2025, filed April 3, 2026not identifiednot identifiednot identified
LFTD Partners Inc.FY 2025, filed April 1, 2026not identifiednot identifiednot identified

Item 1C, verbatim from the filing

The text below is the Cybersecurity item of Oncotelic Therapeutics, Inc.'s Form 10-K as filed with the SEC on April 15, 2026, reproduced word for word from the filing on sec.gov. Page numbers and navigation lines have been removed; nothing has been added. It describes governance as of that date.

ITEM

1C. CYBERSECURITY RISK MANAGEMENT, STRATEGY, AND GOVERNANCE.

Risk

management and strategy

The

Company recognizes the critical importance of developing, implementing, and maintaining robust cybersecurity measures to safeguard our

information systems and protect the confidentiality, integrity, and availability of our data.

Managing

Material Risks & Integrated Overall Risk Management

The

Company has strategically integrated cybersecurity risk management into our broader risk management framework to promote a company-wide

culture of cybersecurity risk management. This integration ensures that cybersecurity considerations are an integral part of our decision-making

processes at every level. Our risk management team works to continuously evaluate and address cybersecurity risks in alignment with our

business objectives and operational needs.

Engage

Third-parties on Risk Management, as required

Recognizing

the complexity and evolving nature of cybersecurity threats, the Company plans to engage external experts, including cybersecurity assessors

and auditors in evaluating and testing our risk management systems. These partnerships would enable us to leverage specialized knowledge

and insights, ensuring our cybersecurity strategies and processes remain at the forefront of industry best practices. Our possible collaborations

with these third-parties will include regular audits, threat assessments, and consultation on security enhancements.

Oversee

Third-party Risk

Because

we are aware of the risks associated with third-party service providers, the Company plans to implement processes to oversee and manage

these risks. We plan to conduct thorough security assessments of all third-party providers before engagement and maintain ongoing monitoring

to ensure compliance with our cybersecurity standards. The monitoring will include periodic assessments by our Chief Executive Officer

("CEO"). This approach will be planned to design to mitigate risks related to data breaches or other security incidents originating

from third-parties.

Risks

from Cybersecurity Threats

We

have no t encountered cybersecurity challenges that have materially impaired our operations or financial standing.

Governance

The

Board of Directors is acutely aware of the critical nature of managing risks associated with cybersecurity threats. The Board plans to

establish robust oversight mechanisms to ensure effective governance in managing risks associated with cybersecurity threats because

we recognize the significance of these threats to our operational integrity and stakeholder confidence,

Board

of Directors Oversight

In

the absence of a functional Audit Committee at this time, the full Board of Directors is responsible to oversight the cybersecurity risks

for the Company.

Management's

Role Managing Risk

The

CEO plays a pivotal role in informing the Board of Directors on cybersecurity risks. The CEO provides comprehensive briefings to the

Audit Committee on a regular basis, with a minimum frequency of once per year. These briefings encompass a broad range of topics, including:

●

Current

cybersecurity landscape and emerging threats;

●

Status

of ongoing cybersecurity initiatives and strategies;

●

Incident

reports and learnings from any cybersecurity events; and

●

Compliance

with regulatory requirements and industry standards.

The fields above are exact quotes from the stored text. "Not identified" means no supporting sentence was found, not that the company has no such arrangement. A name in a filing is not a record of who holds the seat today: the Wire tracks that.

Browse the whole library at /disclosures, or see who the top security role reports to, by sector. Cite as "CISO Tribune, 10-K cybersecurity governance disclosures" with a link.